- Home
- DRMA vs ONFO Comparison
DRMA vs ONFO Comparison
Compare DRMA & ONFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRMA
- ONFO
- Stock Information
- Founded
- DRMA 2014
- ONFO 2018
- Country
- DRMA United States
- ONFO United States
- Employees
- DRMA N/A
- ONFO N/A
- Industry
- DRMA Biotechnology: Pharmaceutical Preparations
- ONFO Computer Software: Programming Data Processing
- Sector
- DRMA Health Care
- ONFO Technology
- Exchange
- DRMA Nasdaq
- ONFO Nasdaq
- Market Cap
- DRMA 4.5M
- ONFO 5.4M
- IPO Year
- DRMA 2021
- ONFO 2022
- Fundamental
- Price
- DRMA $6.45
- ONFO $1.10
- Analyst Decision
- DRMA Strong Buy
- ONFO
- Analyst Count
- DRMA 1
- ONFO 0
- Target Price
- DRMA $3.00
- ONFO N/A
- AVG Volume (30 Days)
- DRMA 23.7K
- ONFO 96.3K
- Earning Date
- DRMA 08-11-2025
- ONFO 08-13-2025
- Dividend Yield
- DRMA N/A
- ONFO N/A
- EPS Growth
- DRMA N/A
- ONFO N/A
- EPS
- DRMA N/A
- ONFO N/A
- Revenue
- DRMA N/A
- ONFO $9,087,118.00
- Revenue This Year
- DRMA N/A
- ONFO N/A
- Revenue Next Year
- DRMA N/A
- ONFO N/A
- P/E Ratio
- DRMA N/A
- ONFO N/A
- Revenue Growth
- DRMA N/A
- ONFO 65.97
- 52 Week Low
- DRMA $5.74
- ONFO $0.61
- 52 Week High
- DRMA $37.90
- ONFO $1.88
- Technical
- Relative Strength Index (RSI)
- DRMA 43.91
- ONFO 46.96
- Support Level
- DRMA $5.94
- ONFO $1.25
- Resistance Level
- DRMA $7.33
- ONFO $1.29
- Average True Range (ATR)
- DRMA 0.63
- ONFO 0.15
- MACD
- DRMA -0.05
- ONFO -0.02
- Stochastic Oscillator
- DRMA 27.68
- ONFO 14.89
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place. The company operates in two business segments: Business to Business (B2B) and Business to Consumers (B2C). The majority of its revenue is generated from the Business-to-Business (B2B) segment, which includes the results of operations of Eastern Standard, RevenueZen, DDS Rank, SEO Butler, Contentellect, DealPipe, and Onfolio LLC.